Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orbactiv Safety in ABSSSI Patients on Warfarin
NCT02452918Phase 4Completed
- Sponsor
- The Medicines Company
- Start
- Sep 2015
- Primary completion
- Jul 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI), sponsored by The Medicines Company. Started Sep 2015; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02452918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452918.